Cancer

News

Novartis set to overcome $14 billion patent cliff say analys...

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said.

News

Lead Pharma signs $308m immune drug deal with Roche

Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases.

News

Fresh doubts over BMS' merger payout as FDA delays key drug ...

Holders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out after the company said COVID-19 travel restrictions are delaying a key re

News

Can in vivo imaging deliver the full potential of immunotherapy

German biotech CatalYm raises €50 million for GDF-15 inhibit...

CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15).

News

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated p

News

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

Novartis set to overcome $14 billion patent cliff say analys...

Lead Pharma signs $308m immune drug deal with Roche

Fresh doubts over BMS' merger payout as FDA delays key drug ...

German biotech CatalYm raises €50 million for GDF-15 inhibit...

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

NICE backs chemo-free CLL combination from AbbVie and Roche

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks